What does this research mean for the field?

Patients with polycythemia vera in the United States experience a substantial disease and treatment burden, including high rates of thromboembolism, disease progression to myelofibrosis, and reduced quality of life and productivity due to phlebotomy, despite receiving current standard of care. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

June 6, 2026Expert Review of Hematology

Burden of thromboembolism, disease progression, and phlebotomy among polycythemia vera patients in the United States: a systematic literature review

View Full Paper

Ask AI

Bookmark

Authors

NPNaveen PemmarajuThe University of Texas MD Anderson Cancer Center QFQi FanTakeda (United States)SRSarah RonnebaumThermo Fisher Scientific (United States)

Discussion

Member takes

Overview

Systematic review shows thromboembolism and phlebotomy burden affects quality of life in polycythemia vera patients.

Key Points

This systematic review aims to characterize the burden of thromboembolism, disease progression, and phlebotomy in patients with polycythemia vera in the United States.
Conducted a systematic literature review using Embase, MEDLINE, and other databases up to June 2025.
Identified and synthesized evidence from 35 unique studies published since 2014.
Analyzed the impact of thromboembolism, treatment, and disease progression on patient outcomes.
Polycythemia vera patients experienced 1.4 to 6.5 thromboembolism events per 100 patients per year.
Higher healthcare costs and mortality risks were associated with thromboembolism; patients with TEs had increased resource utilization.
Disease progression to myelofibrosis was noted in 2.3%-19.9% of patients.

Cite This Study

Pemmaraju et al. (2026) studied this question.

synapsesocial.com/papers/6a23b96a71a5da9775e7550b https://doi.org/10.1080/17474086.2026.2683032

View Full Paper

Ask AI

Bookmark

June 6, 2026Expert Review of Hematology

Burden of thromboembolism, disease progression, and phlebotomy among polycythemia vera patients in the United States: a systematic literature review

View Full Paper

Ask AI

Bookmark

Authors

NPNaveen PemmarajuThe University of Texas MD Anderson Cancer Center QFQi FanTakeda (United States)SRSarah RonnebaumThermo Fisher Scientific (United States)

Discussion

Member takes

Overview

Systematic review shows thromboembolism and phlebotomy burden affects quality of life in polycythemia vera patients.

Key Points

This systematic review aims to characterize the burden of thromboembolism, disease progression, and phlebotomy in patients with polycythemia vera in the United States.
Conducted a systematic literature review using Embase, MEDLINE, and other databases up to June 2025.
Identified and synthesized evidence from 35 unique studies published since 2014.
Analyzed the impact of thromboembolism, treatment, and disease progression on patient outcomes.
Polycythemia vera patients experienced 1.4 to 6.5 thromboembolism events per 100 patients per year.
Higher healthcare costs and mortality risks were associated with thromboembolism; patients with TEs had increased resource utilization.
Disease progression to myelofibrosis was noted in 2.3%-19.9% of patients.

Cite This Study

Pemmaraju et al. (2026) studied this question.

synapsesocial.com/papers/6a23b96a71a5da9775e7550b https://doi.org/10.1080/17474086.2026.2683032

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark